Aviv Regev


Aviv Regev is a computational biologist at the Broad Institute of MIT and Harvard, Professor at the Department of Biology at Massachusetts Institute of Technology and Investigator at the Howard Hughes Medical Institute. Effective August 1, 2020, she is slated to become head of Genentech research and early development.

Education

Regev studied as an Adi Lautman Interdisciplinary Programme for Outstanding Students at Tel Aviv University, where she completed her Ph.D. under the supervision of Eva Jablonka and Ehud Shapiro.

Career and research

Regev served as the Core Institute Member, Chair of the Faculty, and Co-director of the Cell Circuits Program at the Broad Institute. On May 11, 2020, Roche announced that Dr. Regev will be the Head of Genentech Research and Early Development and become a member of the enlarged Corporate Executive Committee on August 1, 2020. She will be based in South San Francisco.
Regev's highly cited research includes work on gene expression, and the use of π-calculus to represent biochemical processes. Regev’s team has been a leading pioneer of single-cell genomics experimental and computational methods.

Awards and honors

Regev was awarded the Overton Prize in 2008 for "outstanding accomplishment to a scientist in the early to mid stage of his or her career". She was awarded the ISCB Innovator Award in 2017. In 2008, she was also awarded the NIH Director's Pioneer Award. She has also been awarded the Burroughs Wellcome Fund Career Award. In 2017, she was awarded a Paul Marks Prize for Cancer Research. She was elected a member of the National Academy of Sciences in 2019.